Literature DB >> 26076947

Aortic disease: Losartan versus atenolol in the Marfan aorta-how to treat?

Romy Franken1, Barbara J M Mulder1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26076947     DOI： 10.1038/nrcardio.2015.95

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  9 in total

1.  Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.

Authors:  Maarten Groenink; Alexander W den Hartog; Romy Franken; Teodora Radonic; Vivian de Waard; Janneke Timmermans; Arthur J Scholte; Maarten P van den Berg; Anje M Spijkerboer; Henk A Marquering; Aeilko H Zwinderman; Barbara J M Mulder
Journal:  Eur Heart J       Date:  2013-09-02       Impact factor: 29.983

2.  Marfan Sartan: a randomized, double-blind, placebo-controlled trial.

Authors:  Olivier Milleron; Florence Arnoult; Jacques Ropers; Philippe Aegerter; Delphine Detaint; Gabriel Delorme; David Attias; Florence Tubach; Sophie Dupuis-Girod; Henry Plauchu; Martine Barthelet; Francois Sassolas; Nicolas Pangaud; Sophie Naudion; Julie Thomas-Chabaneix; Yves Dulac; Thomas Edouard; Jean-Eric Wolf; Laurence Faivre; Sylvie Odent; Adeline Basquin; Gilbert Habib; Patrick Collignon; Catherine Boileau; Guillaume Jondeau
Journal:  Eur Heart J       Date:  2015-05-02       Impact factor: 29.983

3.  Atenolol versus losartan in children and young adults with Marfan's syndrome.

Authors:  Ronald V Lacro; Harry C Dietz; Lynn A Sleeper; Anji T Yetman; Timothy J Bradley; Steven D Colan; Gail D Pearson; E Seda Selamet Tierney; Jami C Levine; Andrew M Atz; D Woodrow Benson; Alan C Braverman; Shan Chen; Julie De Backer; Bruce D Gelb; Paul D Grossfeld; Gloria L Klein; Wyman W Lai; Aimee Liou; Bart L Loeys; Larry W Markham; Aaron K Olson; Stephen M Paridon; Victoria L Pemberton; Mary Ella Pierpont; Reed E Pyeritz; Elizabeth Radojewski; Mary J Roman; Angela M Sharkey; Mario P Stylianou; Stephanie Burns Wechsler; Luciana T Young; Lynn Mahony
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

Review 4.  Current and future pharmacological treatment strategies with regard to aortic disease in Marfan syndrome.

Authors:  Alexander W Hartog; Romy Franken; Aeilko H Zwinderman; Maarten Groenink; Barbara J M Mulder
Journal:  Expert Opin Pharmacother       Date:  2012-03-07       Impact factor: 3.889

5.  Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome.

Authors:  Romy Franken; Alexander W den Hartog; Teodora Radonic; Dimitra Micha; Alessandra Maugeri; Fleur S van Dijk; Hanne E Meijers-Heijboer; Janneke Timmermans; Arthur J Scholte; Maarten P van den Berg; Maarten Groenink; Barbara J M Mulder; Aeilko H Zwinderman; Vivian de Waard; Gerard Pals
Journal:  Circ Cardiovasc Genet       Date:  2015-01-22

6.  Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.

Authors:  Hsin-Hui Chiu; Mei-Hwan Wu; Jou-Kou Wang; Chun-Wei Lu; Shuenn-Nan Chiu; Chun-An Chen; Ming-Tai Lin; Fu-Chang Hu
Journal:  Mayo Clin Proc       Date:  2013-01-12       Impact factor: 7.616

7.  Circulating transforming growth factor-β as a prognostic biomarker in Marfan syndrome.

Authors:  Romy Franken; Alexander W den Hartog; Vivian de Waard; Leo Engele; Teodora Radonic; Rene Lutter; Janneke Timmermans; Arthur J Scholte; Maarten P van den Berg; Aeilko H Zwinderman; Maarten Groenink; Barbara J M Mulder
Journal:  Int J Cardiol       Date:  2013-04-10       Impact factor: 4.164

8.  Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.

Authors:  Benjamin S Brooke; Jennifer P Habashi; Daniel P Judge; Nishant Patel; Bart Loeys; Harry C Dietz
Journal:  N Engl J Med       Date:  2008-06-26       Impact factor: 91.245

9.  Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration.

Authors:  Alex Pitcher; Jonathan Emberson; Ronald V Lacro; Lynn A Sleeper; Mario Stylianou; Lynn Mahony; Gail D Pearson; Maarten Groenink; Barbara J Mulder; Aeilko H Zwinderman; Julie De Backer; Anne M De Paepe; Eloisa Arbustini; Guliz Erdem; Xu Yu Jin; Marcus D Flather; Michael J Mullen; Anne H Child; Alberto Forteza; Arturo Evangelista; Hsin-Hui Chiu; Mei-Hwan Wu; George Sandor; Ami B Bhatt; Mark A Creager; Richard B Devereux; Bart Loeys; J Colin Forfar; Stefan Neubauer; Hugh Watkins; Catherine Boileau; Guillaume Jondeau; Harry C Dietz; Colin Baigent
Journal:  Am Heart J       Date:  2015-02-12       Impact factor: 4.749
  9 in total
  4 in total

Review 1.  Cardiovascular Management of Adults with Marfan Syndrome.

Authors:  Yukiko Isekame; Sabiha Gati; Jose Antonio Aragon-Martin; Rachel Bastiaenen; Sreenivasa Rao Kondapally Seshasai; Anne Child
Journal:  Eur Cardiol       Date:  2016-12

Review 2.  Vascular smooth muscle cells in Marfan syndrome aneurysm: the broken bricks in the aortic wall.

Authors:  Gianluca L Perrucci; Erica Rurali; Aoife Gowran; Alessandro Pini; Carlo Antona; Roberto Chiesa; Giulio Pompilio; Patrizia Nigro
Journal:  Cell Mol Life Sci       Date:  2016-08-17       Impact factor: 9.261

3.  Marfan on the Move.

Authors:  Vivian de Waard
Journal:  J Am Heart Assoc       Date:  2017-09-25       Impact factor: 5.501

4.  Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G/+ Marfan Mouse Model.

Authors:  Stijntje Hibender; Romy Franken; Cindy van Roomen; Anique Ter Braake; Ingeborg van der Made; Edith E Schermer; Quinn Gunst; Maurice J van den Hoff; Esther Lutgens; Yigal M Pinto; Maarten Groenink; Aeilko H Zwinderman; Barbara J M Mulder; Carlie J M de Vries; Vivian de Waard
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-06-09       Impact factor: 8.311
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.